Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 2;11(1):e00120. doi: 10.14309/ctg.0000000000000120

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 1. — Potential mechanisms underlying beneficial effects of Cannabis/cannabinoids in inflammatory bowel disease. (a) Cannabinoids protect the mucosal barrier and promote wound healing (35). Blockade of MGL increases 2-AG levels, which promotes protection in colitis (37). (b) Cannabis/cannabinoids influence the activity of immunocytes and promote apoptosis in T cells (86). (c) The microbiome interacts with the endocannabinoid system in maintaining a healthy barrier (41,42). (d) CB₁ receptors are found in the brain (87) along the gut brain axis (39) and the enteric nervous system. CB₁ receptors in the brain may be essential in the protection against intestinal inflammation (40). 2-AG, 2-arachidonoylglycerol; CB1, cannabinoid 1 receptor; CB2, cannabinoid 2 receptor; and MGL, monoacylglycerol lipase.